This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DETRE, K. M. Articles by SHAW, L. Search for Related Content PubMed PubMed Citation Articles by DETRE, K. M. Articles by SHAW, L.

(Circulation. 1974;50:998.)
© 1974 American Heart Association, Inc.

---

Long-term Changes of Serum Cholesterol with Cholesterol-altering Drugs in Patients with Coronary Heart Disease

Veterans Administration Drug-Lipid Cooperative Study

KATHERINE M. DETRE M.D., DR. P.H.¹ LAWRENCE SHAW A.M.¹

¹ From West Haven VA Cooperative Studies Program Support Center, West Haven VA Hospital, West Haven, Connecticut; the Department of Biometry, Yale University, News Haven, Connecticut; the George Washington University, Biostatistics Center, Washington, D.C.

In a controlled secondary prevention trial of estrogen and cholesterol-lowering drugs on 570 veterans, all of whom had had one or more episodes of acute myocardial infarction, changes in serum cholesterol were followed for at least five years. The findings included the following:

1) Estrogen, 1.25 mg daily, had no appreciable effect on cholesterol level.

2) Aluminum nicotinate, 4 g/day, resulted in a 20% reduction in cholesterol level for about 2 years after which levels slowly rose to a level 12% below the baseline level in good adherers; poor adherers had smaller ultimate changes.

3) Dextrothyroxine, 4 mg/day, had a sustained cholesterol-lowering effect of approximately 7% throughout the study.

The above values were obtained after adjusting for an underlying upward trend in all cholesterol values during the five-year observation period.

4) Discontinuation of both aluminum nicotinate and dextrothyroxine resulted in a significant rise in cholesterol within three months.

5) The 6% rise in the cholesterol level found in the control group over five years of follow-up could be attributed to aging and laboratory drift.

6) Regression toward the mean rather than pharmacological effect accounted for the greater response to treatment of patients with high initial cholesterol.

Key Words: Secondary prevention trial • Dextrothyroxine • Age and cholesterol • Myocardial infarction • Aluminum nicotinate • Estrogen • Double-blind design

Submitted on January 18, 1974
Accepted on June 27, 1974

This article has been cited by other articles:

				G. Assmann, P. Cullen, F. Jossa, B. Lewis, and M. Mancini Coronary Heart Disease: Reducing the Risk : The Scientific Background to Primary and Secondary Prevention of Coronary Heart DiseaseA Worldwide View Arterioscler. Thromb. Vasc. Biol., August 1, 1999; 19(8): 1819 - 1824. [Full Text] [PDF]